Experimental animal models for the study of therapeutic approaches in renal cell carcinoma.
Renal cell cancer is a common malignancy with a poor response to multiple therapeutic modalities. Immunotherapy is the most promising of the various treatment approaches tried. Recently, Interleukin-2 has been approved by the Food and Drug Administration for the treatment of metastatic kidney cancer. However, the relatively low response rate (15-30%) and the limiting toxicity of immunotherapy regimens stress the need to develop new therapeutic modalities. Experimental animal models are instrumental in the development of new treatment alternatives. We describe several of the animal models available for the study of kidney cancer and discuss on-going preclinical investigations in the murine renal adenocarcinoma system (Renca), the Wistar-Lewis rat model, and human renal cancer xenograft models in immunodeficient mice.
Hillman
G G
GG
Department of Urology, Wayne State University School of Medicine, Detroit, MI 48201.
Droz
J P
JP
Haas
G P
GP
D000818:Animals; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D005260:Female; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000628:therapy*; D051381:Rats; D011917:Rats, Inbred Lew; D017208:Rats, Wistar; D014183:Transplantation, Heterologous